DGAP-Adhoc: B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG in concluding negotiations for takeover of majority stake of enzyme producer Biocatalysts Ltd.

DGAP-Ad-hoc: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Investment/Mergers & Acquisitions B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN AG in concluding negotiations for takeover of majority stake of enzyme producer Biocatalysts Ltd. 16-March-2018 / 17:51 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- BRAIN AG in concluding negotiations for takeover of majority stake of enzyme producer Biocatalysts Ltd. Zwingenberg, Germany 16 March 2018 Today, the bio-economy company BRAIN AG (together with its subsidiaries the "BRAIN Group" or "BRAIN") announces that the signing of a share purchase agreement between BRAIN and Biocatalysts Ltd. based in Cardiff, Great Britain, and active in the field of speciality enzymes is in concluding negotiations. Therein the takeover of the majority stake of Biocatalysts's shares by BRAIN is governed. The transaction is planned to be completed within the first quarter of 2018. The Supervisory Board of BRAIN AG was informed about the process and granted its approval to the transaction. Biocatalysts is a biotechnology company focused on the product development, production and distribution of speciality enzymes for various industries such as food and fine chemicals. BRAIN is a leading technology company in the field of industrial biotechnology, developing microorganisms, natural substances and enzymes for the industrial use. The completion of the strategic acquisition of a majority stake in Biocatalysts is intended to accelerate product driven growth in attractive speciality enzyme markets, broaden the portfolio of the enzyme business of BRAIN and achieve synergies with respect to research and development as well as production and global distribution. After the expected completion of the transaction, Biocatalysts Ltd. will continue to operate under the current company name. Biocatalysts Ltd. is profitable and generated revenues of approximately EUR 9.03 million* (£ 7.978 million) in the 2015/2016 financial year and. The revenue for the financial year 2016/17 is EUR 10.81 million* (£ 9,546 Mio.), which corresponds to a growth rate of 19.7% compared to the previous year. Biocatalysts Ltd.'s turnover has grown by an compound annual growth rate (CAGR) of 12% between 2014/15 and 2016/17. +++END+++ * Average Exchange Rate of February 2018: 1 GBP = 1.132 EUR (Source: Oanda) Contact: BžRžAžIžN Biotechnology Research And Information Network AG Darmstädter Str. 34-36 64673 Zwingenberg Germany www.brain-biotech.de IR Contact Dr. Martin Langer Executive Vice President Corporate Development Tel.: +49-(0)-6251-9331-16 Fax: +49-(0)-6251-9331-11 E-Mail: ir@brain-biotech.de Media Contact Thomas Deichmann Head of Public Relations Tel.: +49-(0)-6251-9331-72 Fax: +49-(0)-6251-9331-11 E-Mail: td@brain-biotech.de About BRAIN B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN's business model is based on two pillars - BioScience and BioIndustrial. The BioScience comprises its frequently exclusive collaboration business with industrial partners. BioIndustrial comprises the development and commercialization of BRAIN's own products and active product components. Further information is available at www.brain-biotech.de/en. Disclaimer This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements. --------------------------------------------------------------------------- 16-March-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: B.R.A.I.N. Biotechnology Research And Information Network AG Darmstädter Straße 34-36 64673 Zwingenberg Germany Phone: +49 (0) 62 51 / 9331-0 Fax: +49 (0) 62 51 / 9331-11 E-mail: ir@brain-biotech.de Internet: www.brain-biotech.de ISIN: DE0005203947 WKN: 520394 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange End of Announcement DGAP News Service --------------------------------------------------------------------------- 665255 16-March-2018 CET/CEST

Die wichtigsten Finanzdaten auf einen Blick
  2013 2014 2015 2016 2017 2018 2019 2020e
Umsatzerlöse1 8,76 10,37 21,13 22,79 24,11 27,05 38,56 43,00
EBITDA1,2 -3,72 -3,81 -3,10 -12,36 -7,70 -6,55 -2,47 -0,50
EBITDA-Marge3 -42,47 -36,74 -14,67 -54,23 -31,94 -24,21 -6,41 -1,16
EBIT1,4 -4,39 -4,82 -4,57 -13,81 -9,37 -9,57 -7,17 -3,70
EBIT-Marge5 -50,11 -46,48 -21,63 -60,60 -38,86 -35,38 -18,59 -8,60
Jahresüberschuss1 0,00 -4,52 -5,47 -14,43 -9,40 -8,37 -10,49 -4,90
Netto-Marge6 0,00 -43,59 -25,89 -63,32 -38,99 -30,94 -27,20 -11,40
Cashflow1,7 -4,85 -3,90 -4,11 -8,68 -5,80 -5,42 -3,38 -1,10
Ergebnis je Aktie8 -0,28 -0,33 -0.36 -0,97 -0,58 -0,45 -0,58 -0,27
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2019 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Ernst & Young

BRAIN Biotechology
WKN Kurs in € Einschätzung Börsenwert in Mio. €
520394 8,300 164,80
KGV 2021e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 17,17 0,000 -17,40
13,47 - 4,27 -73,834
Dividende '19 in € Dividende '20e in € Div.-Rendite '19e
in %
0,00 0,00 0,00 05.03.2020
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
28.02.2020 29.05.2020 31.08.2020 14.01.2020
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-3,00% -11,10% -23,15% -17,00%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu B.R.A.I.N. Biotechnology Research And Information Network AG  ISIN: DE0005203947 können Sie bei DGAP abrufen

Biotechnologie , 520394 , BNN , XETR:BNN